Silver crumbs and silver crumb arthritis cause great distress to the lives of patients, especially in cases of difficult treatment, where traditional treatments are often ineffective. In recent years, joint oral treatment programmes for JAK or TYK2 inhibitors have brought new light to these patients.
Silver crumbs are a common chronic inflammatory skin disease, characterized by red spots and crumbs on the skin, which not only affect the skin but may also lead to ailments, pain, etc. In addition to skin symptoms, silver crumbs have a graft and joints, causing joint pain, swelling, rigidity and even deformity, which seriously affects the mobility and quality of life of patients.
In the past, it was often difficult to achieve the desired results of a single treatment for difficult silver crumbs and silver crumbs. However, with further medical research, the emergence of biological agents provides new avenues for treatment. Biological agents are able to target precisely specific molecules that are active in the immune system, such as tumour cause of death (TNF), white cellulose (IL), etc., thus effectively inhibiting inflammatory reactions and mitigating skin and joint symptoms.
However, it is difficult for some patients to fully control their condition even if they use biological agents, which prompts the exploration of joint treatment programmes. JAK (Janus hormonal enzyme) and TYK2 (chesaine sterase 2) inhibitors, as a new type of oral drug, further regulate the immune system and inhibit the activation and multiplication of inflammatory cells by blocking signal-transmission routes within cells.
The case series found encouraging results in some difficult cases when biological agents were used in combination with oral JAK or TYK2 inhibitors. For patients who are less responsive to the treatment of single biological agents, there has been a marked reduction in red spots and scabs in the skin after combined treatment, a significant reduction in joint pain and swelling and an improvement in joint activity. For example, a patient who has been chronically affected by silver crumb arthritis, who was treated with a single biological agent, continues to experience frequent joint pains, seriously affecting daily walking and work. The combination of biological agents and JAK inhibitors has led to a significant reduction in the number of joint pain episodes, a gradual reduction in skin symptoms and a significant improvement in the quality of life.
The advantage of this joint treatment programme lies in the complementarity of its mechanisms. Biological agents intervene primarily in the direction of cytogens in the immune system, while JAK or TYK2 inhibitors further regulate the immune response from the point of view of intracellular signal transmission, and the synergies between the two enable more comprehensive and deep suppression of over-active immune systems and thus better control inflammation.
However, as with any treatment, joint treatment does not apply to all patients and may have some side effects. Common side effects may include increased risk of infection, inadequate gastrointestinal tracts and abnormal blood system. Thus, before joint treatment is carried out, doctors conduct a comprehensive assessment of the patient, including his/her severity, condition, combinations, etc., weigh the benefits and risks of treatment and develop individualized treatment programmes for the patient.
The combination oral treatment of JAK or TYK2 inhibitors offers a new and effective treatment option for patients with difficult and dissuasive silver crumbs and silver crumb arthritis, but it needs to be used carefully, under the guidance of a specialist physician, to closely monitor the response and adverse reactions in the treatment to ensure that the patient is able to obtain the best treatment and safety and regain confidence in health and life.
